JP2015517500A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517500A5 JP2015517500A5 JP2015511684A JP2015511684A JP2015517500A5 JP 2015517500 A5 JP2015517500 A5 JP 2015517500A5 JP 2015511684 A JP2015511684 A JP 2015511684A JP 2015511684 A JP2015511684 A JP 2015511684A JP 2015517500 A5 JP2015517500 A5 JP 2015517500A5
- Authority
- JP
- Japan
- Prior art keywords
- mcm
- use according
- cells
- subunit
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010051862 Methylmalonyl-CoA mutase Proteins 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 10
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 5
- QEEBRPGZBVVINN-UHFFFAOYSA-N Desacetyl-bufotalin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C1(O)CCC2C=1C=CC(=O)OC=1 QEEBRPGZBVVINN-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- QEEBRPGZBVVINN-BMPKRDENSA-N bufalin Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)CC[C@@]32C)C=CC(=O)OC=1 QEEBRPGZBVVINN-BMPKRDENSA-N 0.000 claims 2
- 238000012790 confirmation Methods 0.000 claims 2
- 150000002009 diols Chemical class 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004940 nucleus Anatomy 0.000 claims 2
- 108091006112 ATPases Proteins 0.000 claims 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims 1
- 238000010599 BrdU assay Methods 0.000 claims 1
- 108010077544 Chromatin Proteins 0.000 claims 1
- 230000004543 DNA replication Effects 0.000 claims 1
- 230000010190 G1 phase Effects 0.000 claims 1
- 101001126977 Homo sapiens Methylmalonyl-CoA mutase, mitochondrial Proteins 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000018199 S phase Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003483 chromatin Anatomy 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000009088 enzymatic function Effects 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 102000034287 fluorescent proteins Human genes 0.000 claims 1
- 108091006047 fluorescent proteins Proteins 0.000 claims 1
- 238000012744 immunostaining Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000010399 physical interaction Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644442P | 2012-05-09 | 2012-05-09 | |
| US61/644,442 | 2012-05-09 | ||
| PCT/US2013/040287 WO2013169989A1 (en) | 2012-05-09 | 2013-05-09 | Method and compounds for inhibiting the mcm complex and their application in cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018002988A Division JP2018100274A (ja) | 2012-05-09 | 2018-01-11 | Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517500A JP2015517500A (ja) | 2015-06-22 |
| JP2015517500A5 true JP2015517500A5 (enExample) | 2016-06-23 |
Family
ID=49551267
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511684A Pending JP2015517500A (ja) | 2012-05-09 | 2013-05-09 | Ｍｃｍ複合体を阻害するための方法および化合物ならびにガン処置におけるそれらの適用 |
| JP2018002988A Pending JP2018100274A (ja) | 2012-05-09 | 2018-01-11 | Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法 |
| JP2019237597A Pending JP2020073544A (ja) | 2012-05-09 | 2019-12-27 | Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法 |
| JP2021150771A Pending JP2021193132A (ja) | 2012-05-09 | 2021-09-16 | Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法 |
| JP2023154199A Pending JP2024001049A (ja) | 2012-05-09 | 2023-09-21 | Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法 |
| JP2025134199A Pending JP2025169320A (ja) | 2012-05-09 | 2025-08-12 | Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018002988A Pending JP2018100274A (ja) | 2012-05-09 | 2018-01-11 | Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法 |
| JP2019237597A Pending JP2020073544A (ja) | 2012-05-09 | 2019-12-27 | Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法 |
| JP2021150771A Pending JP2021193132A (ja) | 2012-05-09 | 2021-09-16 | Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法 |
| JP2023154199A Pending JP2024001049A (ja) | 2012-05-09 | 2023-09-21 | Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法 |
| JP2025134199A Pending JP2025169320A (ja) | 2012-05-09 | 2025-08-12 | Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11648258B2 (enExample) |
| EP (2) | EP2846807B1 (enExample) |
| JP (6) | JP2015517500A (enExample) |
| CN (2) | CN110412285B (enExample) |
| AU (1) | AU2013259486B2 (enExample) |
| CA (2) | CA2873283C (enExample) |
| ES (1) | ES2949335T3 (enExample) |
| IN (1) | IN2014MN02513A (enExample) |
| WO (1) | WO2013169989A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019283946B2 (en) * | 2017-05-19 | 2021-05-20 | Enkang Pharmaceuticals (Guangzhou), Ltd. | Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms |
| CN117756875A (zh) | 2017-05-19 | 2024-03-26 | 恩康药业科技（广州）有限公司 | 黄夹次甙乙多晶型的晶型特征、制备方法及在抗癌上的应用 |
| CN114129582A (zh) * | 2019-03-27 | 2022-03-04 | 天津中医药大学 | 黄夹次乙苷作为抗肿瘤药物的应用 |
| WO2025077888A1 (zh) | 2023-10-13 | 2025-04-17 | 恩康药业科技（广州）有限公司 | 一种适合外用的化合物及药物组合物 |
| EP4792817A1 (en) | 2023-10-13 | 2026-08-19 | EnKang Pharmaceuticals (Guangzhou), Ltd. | Compound and method for treating and/or preventing skin cancer or precancerous lesion thereof |
| WO2025077886A1 (zh) | 2023-10-13 | 2025-04-17 | 恩康药业科技（广州）有限公司 | 治疗和/或预防日光性角化病的化合物及方法 |
| JP2025107691A (ja) | 2024-01-09 | 2025-07-22 | シャープ株式会社 | 端末装置、方法、および集積回路 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0592990A (ja) | 1991-08-06 | 1993-04-16 | Taisho Pharmaceut Co Ltd | カルデノライド誘導体 |
| WO2002014343A1 (en) | 2000-08-17 | 2002-02-21 | Terness, Peter | Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents |
| US7393950B2 (en) | 2002-08-29 | 2008-07-01 | Hong Kong University Of Science & Technology | Antisense oligonucleotides targeted to human CDC45 |
| US8318922B2 (en) | 2002-08-29 | 2012-11-27 | The Hong Kong Polytechnic University | Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins |
| JP2004131435A (ja) | 2002-10-11 | 2004-04-30 | Mitsubishi Chemicals Corp | 抗癌剤のスクリーニング方法及び組織の癌化の判定方法 |
| DE10248751A1 (de) | 2002-10-18 | 2004-05-06 | Berdel, Wolfgang E., Prof. Dr.med. | Dyslokalisationsmoleküle und deren Verwendung |
| US20070207120A1 (en) | 2004-04-14 | 2007-09-06 | Sarah Drayton | Selective Killing Of Cancer Cells By Induction Of Acetyltransferase Via Tnf-Alpha And Il-6 |
| NZ556158A (en) | 2004-12-22 | 2010-04-30 | Auckland Uniservices Ltd | Trefoil factors and methods of treating proliferation disorders using same |
| EP1787645A1 (en) | 2005-11-18 | 2007-05-23 | Institut Curie | New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway |
| US20090018088A1 (en) * | 2006-10-27 | 2009-01-15 | University Of Louisville Research Foundation | Treating cancer with cardiac glycosides |
| CN101683359B (zh) * | 2008-09-28 | 2012-05-09 | 上海秀新臣邦医药科技有限公司 | 一种治疗肿瘤的中药组合物及其制备方法 |
| CN101726577A (zh) * | 2008-10-13 | 2010-06-09 | 中山大学 | 通过干扰巢蛋白表达来筛选抑制肿瘤增殖和促进细胞凋亡的药物的方法 |
| WO2010068247A1 (en) | 2008-12-10 | 2010-06-17 | Sloan-Kettering Institute For Cancer Research | Cardenolides for the treatment of ocular cancer |
| CN102219821A (zh) | 2011-05-05 | 2011-10-19 | 沈阳药科大学 | 一类强心苷类化合物及其抗肿瘤用途 |
-
2013
- 2013-05-09 CA CA2873283A patent/CA2873283C/en active Active
- 2013-05-09 JP JP2015511684A patent/JP2015517500A/ja active Pending
- 2013-05-09 AU AU2013259486A patent/AU2013259486B2/en active Active
- 2013-05-09 IN IN2513MUN2014 patent/IN2014MN02513A/en unknown
- 2013-05-09 EP EP13787939.1A patent/EP2846807B1/en active Active
- 2013-05-09 EP EP23177484.5A patent/EP4248978A3/en active Pending
- 2013-05-09 WO PCT/US2013/040287 patent/WO2013169989A1/en not_active Ceased
- 2013-05-09 CN CN201910489605.4A patent/CN110412285B/zh active Active
- 2013-05-09 ES ES13787939T patent/ES2949335T3/es active Active
- 2013-05-09 CN CN201380024370.2A patent/CN104736157B/zh active Active
- 2013-05-09 CA CA3111702A patent/CA3111702C/en not_active Withdrawn - After Issue
- 2013-05-09 US US14/399,960 patent/US11648258B2/en active Active
-
2018
- 2018-01-11 JP JP2018002988A patent/JP2018100274A/ja active Pending
-
2019
- 2019-12-27 JP JP2019237597A patent/JP2020073544A/ja active Pending
-
2021
- 2021-09-16 JP JP2021150771A patent/JP2021193132A/ja active Pending
-
2023
- 2023-09-21 JP JP2023154199A patent/JP2024001049A/ja active Pending
-
2025
- 2025-08-12 JP JP2025134199A patent/JP2025169320A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Duncan et al. | Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer | |
| Do et al. | Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion | |
| Chang et al. | HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer | |
| Liu et al. | The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21WAF1/CIP1 expression | |
| US12233060B2 (en) | Inhibitors of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancer | |
| Yang et al. | Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells | |
| Huang et al. | Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase | |
| Ling et al. | Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells Corrigendum in/10.3892/mmr. 2022.12691 | |
| BR112016017986A2 (pt) | anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos de produção de um anticorpo, de tratamento do câncer, de tratamento de uma doença e de detecção de jagged1 humana em uma amostra biológica, imunoconjugado, formulação farmacêutica e uso do anticorpo | |
| JP2014144959A5 (enExample) | ||
| AR088514A1 (es) | Inmunoligantes biespecificos dirigidos contra tnf | |
| Advani et al. | Precision oncology, signaling, and anticancer agents in cancer therapeutics | |
| BR112015029788A2 (pt) | hetero-multímero, construto de anticorpo isolado, ácido nucleico, célula hospedeira, método para preparar o hetero-multímero, composição farmacêutica, método para tratar uma doença, uso do hetero-multímero, uso de uma quantia terapêutica do hetero-multímero e método para reduzir a função efetora de um construto de anticorpo | |
| EA201892774A1 (ru) | Антитела | |
| RU2014133069A (ru) | Транслокации r-спондина и способы с их использованием | |
| Lorusso et al. | miRNAs as key players in the management of cutaneous melanoma | |
| Wu et al. | Smoothened antagonist GDC‑0449 (Vismodegib) inhibits proliferation and triggers apoptosis in colon cancer cell lines Corrigendum in/10.3892/etm. 2025.12885 | |
| Yu et al. | Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity | |
| BR112014029089A2 (pt) | anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2 | |
| Waresijiang et al. | The downregulation of miR-125a-5p functions as a tumor suppressor by directly targeting MMP-11 in osteosarcoma | |
| WO2017217807A3 (ko) | Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물 | |
| Zhang et al. | Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors | |
| Kim et al. | ELK3-GATA3 axis modulates MDA-MB-231 metastasis by regulating cell-cell adhesion-related genes | |
| RU2016135933A (ru) | Композиция для противоракового вспомогательного лекарственного средства, содержащая средство, индуцирующее экспрессию rip3, в качестве активного ингредиента, способ скрининга противоракового вспомогательного лекарственного средства, повышающего чувствительность к противораковому лекарственному средству путем стимуляции экспрессии rip3, и способ контроля чувствительности к противораковому лекарственному средству | |
| An et al. | Circulating microvesicles from pancreatic cancer accelerate the migration and proliferation of PANC-1 cells |